Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Northstar Gold Signs MOU with Hunan Nonferrous Ltd. to Develop Gold Resource (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Vanda Pharmaceuticals Inc VNDA

Healthcare Biotechnology
Vanda Pharmaceuticals Inc. is a biopharmaceutical company, which is focused on the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. The Company’s commercial portfolio is comprised of three products: HETLIOZ for the treatment of non-24-hour sleep-wake disorder (Non-24) and for the treatment of nighttime sleep disturbances in smith-magenis syndrome (SMS), Fanapt (iloperidone) for the treatment of bipolar I disorder and a long acting injectable (LAI) formulation for the treatment of schizophrenia, and PONVORY (ponesimod) for the treatment of inflammatory/autoimmune disorders, including ulcerative colitis, psoriasis, Crohn's disease, atopic dermatitis, eosinophilic esophagitis and alopecia areata. The Company also has a range of drugs in development, including Tradipitant (VLY-686), VHX-896, VSJ-110, VPO-227, VTR-297, VQW-765, VCA-894A and Type 2S (CMT2S).


NDAQ:VNDA - Post by User

Vanda Pharmaceuticals Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(169)
•••
Post by whytestockson Jun 06, 2024 12:45pm
22 Views
Post# 36075619

Vanda Pharmaceuticals Receives Another Takeover Proposal, Co

Vanda Pharmaceuticals Receives Another Takeover Proposal, Co
Breaking News: $VNDA Vanda Pharmaceuticals Receives Another Takeover Proposal, Considers $466M Deal | BenzingaVanda Pharmaceuticals Inc. (NASDAQ:VNDA) received an acquisition offer from Cycle Pharmaceuticals Ltd worth $8 per share, representing a total cash...VNDA - Vanda Pharmaceuticals Receives Another Takeover Proposal, Considers $466M Deal | Benzinga

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities